Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels

Diabetes Technology & Therapeutics
Manuel González-OrtizEsperanza Martínez-Abundis

Abstract

Currently, it is still unknown whether differences in glycemic control have any effect on glucose and insulin kinetics after vildagliptin administration. The aim of this study was to evaluate the effect of vildagliptin on glucose and insulin concentrations during a 24-h period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c (A1C) levels. A randomized, double-blind, crossover, placebo-controlled clinical trial was carried out in 12 drug-naive adult volunteers with type 2 diabetes and overweight or obesity. Subjects had fasting glucose values between 7.2 and 13.3 mmol/L. Six patients had A1C between 7.0% and 8.4% (Group A), and the remaining subjects had A1C between 8.5% and 10.0% (Group B). Patients received oral administration of vildagliptin (50 mg twice daily) or placebo in a crossover manner for two consecutive days. Until the second day of the interventions, glucose and insulin concentrations were measured every hour during a 24-h period, and areas under the curve (AUCs) were calculated. Statistical analyses were evaluated with Wilcoxon and Mann-Whitney U tests. There were significant decreases in glucose concentrations after vildagliptin administration in both groups when comparing placebo in a...Continue Reading

References

May 30, 2003·American Journal of Physiology. Endocrinology and Metabolism·Ronald L PrigeonDavid A D'Alessio
May 6, 2004·The Journal of Clinical Endocrinology and Metabolism·Bo AhrénAnja Schweizer
Apr 22, 2006·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Louis Monnier, Claude Colette
Mar 6, 2009·Journal of Diabetes and Its Complications·Raffaele MarfellaGiuseppe Paolisso
Jul 8, 2010·Diabetes Research and Clinical Practice·Xiao-min ChenHao-Jie Wu
Jul 27, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·A Ceriello, M A Ihnat
Feb 11, 2011·Diabetes/metabolism Research and Reviews·Matteo MonamiEdoardo Mannucci
May 6, 2011·Diabetes Care·Eberhard StandlAntonio Ceriello
Nov 24, 2011·Diabetes & Metabolism Journal·Hyun Jeong Jeon, Tae Keun Oh

❮ Previous
Next ❯

Methods Mentioned

BETA
ion-exchange

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.